Results 241 to 250 of about 939,495 (280)

Clinical Activity of RET TKI Plus Chemotherapy After Progression on a RET TKI in a <i>RET</i> Fusion-Positive NSCLC Real-World Cohort: A Brief Report. [PDF]

JTO Clin Res Rep
Paula AG, Liu X, Karimi A, Concannon K, Heeke S, Elamin YY, Wang K, Pozadzides JV, Vokes N, Tu J, Tsao A, Negrao MV, Zhang J, Singhi EK, Zhang B, Rinsurongkawong W, Martins IG, Tran HT, Gibbons DL, Nilsson MB, Heymach JV.   +20 more
europepmc   +1 more source

A case of neoadjuvant targeted therapy with pralsetinib for locally advanced lung adenocarcinoma with RET fusion mutation. [PDF]

J Cardiothorac Surg
Chunmao W, Haijie C, Zitong W, Zhi Y.
europepmc   +1 more source

Accurate <i>RET</i> Fusion Detection in Solid Tumors Using RNA Sequencing Coverage Imbalance Analysis. [PDF]

Int J Mol Sci
Gaziev I, Khristichenko A, Luppov D, Suntsova M, Bondarenko E, Reinberg M, Matrosova A, Khilal N, Sorokin M, Sekacheva M, Poddubskaya E, Buzdin A, Zakharova G.   +12 more
europepmc   +1 more source

Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch. [PDF]

NPJ Precis Oncol
Deschler-Baier B, Krebs M, Kroiss M, Chatterjee M, Gundel D, Kestler C, Kerscher A, Kunzmann V, Appenzeller S, Maurus K, Rosenwald A, Bargou R, Gerhard-Hartmann E, Venkataramani V.   +13 more
europepmc   +1 more source

Case Report: Unclassifiable cerebellar high-grade neuroepithelial tumor with a <i>CCDC6</i>::<i>RET</i> fusion manifesting explosive recurrence. [PDF]

Front Surg
Regmi M, Liu S, Xiong Y, Liu J, Zhao Z, Zhang X, Yang C, Sino-Uzbek Regenerative Therapy Consortium (SURE).   +7 more
europepmc   +1 more source

Development of clinical-radiological prediction models to prioritize <i>ALK</i>, <i>ROS1</i>, and <i>RET</i> fusion testing in major driver alteration-negative non-small cell lung cancer. [PDF]

J Thorac Dis
Wang Y, Xie Y, Yao X, Ke K, Ma P, Wang F, Liu Q, Xie X, Liu M, Lin X, Zhou C, Xie Z.   +11 more
europepmc   +1 more source

Efficacy of selpercatinib as a first-line treatment for <i>RET</i>-fusion positive non-small-cell lung cancer: a novel two-stage Bayesian network meta-analysis. [PDF]

J Comp Eff Res
Forsyth JE, Khanal M, Kiiskinen U, Jyothi A, Goel R, Puri T, Ren S, Sonksen MD, Wang X, Jen MH.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

RET fusions in solid tumors

Cancer Treatment Reviews, 2019
The RET proto-oncogene has been well-studied. RET is involved in many different physiological and developmental functions. When altered, RET mutations influence disease in a variety of organ systems from Hirschsprung's disease and multiple endocrine neoplasia 2 (MEN2) to papillary thyroid carcinoma (PTC) and non-small cell lung cancer (NSCLC).
Michael G McCusker, Alessandro Russo
exaly   +3 more sources